ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Published: 18 May 2021

  • Views:

    Views Icon 686
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Deepak L Bhatt (Brigham and Women's Hospital, Boston, MA, US) discussed the latest data on the benefits of SGLT1/2 inhibition across the full spectrum of ejection fraction, including HFpEF.

Recorded remotely from Boston and Hamilton, 2021. 

Editor: Mirjam Boros

Videography:Tom Green